当前位置: X-MOL 学术Eur. J. Neurol. › 论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
Plasma neurofilament light chain concentrations as a biomarker of clinical and radiologic outcomes in relapsing multiple sclerosis: Post hoc analysis of Phase 3 ozanimod trials
European Journal of Neurology ( IF 5.1 ) Pub Date : 2021-07-22 , DOI: 10.1111/ene.15009
Sarah Harris 1 , Giancarlo Comi 2 , Bruce A C Cree 3 , Douglas L Arnold 4 , Lawrence Steinman 5 , James K Sheffield 1 , Harry Southworth 6 , Ludwig Kappos 7 , Jeffrey A Cohen 8 ,
Affiliation  

We investigated plasma neurofilament light chain concentration (pNfL) as a biomarker for neuroaxonal damage and disease activity using data from Phase 3 trials of ozanimod in relapsing multiple sclerosis (RMS).

中文翻译:

血浆神经丝轻链浓度作为复发性多发性硬化症临床和放射学结果的生物标志物:3 期 ozanimod 试验的事后分析

我们使用来自 ozanimod 在复发性多发性硬化症 (RMS) 中的 3 期试验数据研究了血浆神经丝轻链浓度 (pNfL) 作为神经轴突损伤和疾病活动的生物标志物。
更新日期:2021-07-22
down
wechat
bug